(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ antitumor) (NNS agents))) (PP (IN on) (NP (NP (NN cytotoxicity) (NN induction)) (PP (IN by) (NP (NN sodium) (NN fluoride))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB recently)) (VP (VBN found) (SBAR (IN that) (S (NP (NP (NN sodium) (NN fluoride)) (PRN (-LRB- -LRB-) (NP (NN NaF)) (-RRB- -RRB-))) (VP (VBD induced) (NP (JJ apoptotic) (NN cell) (NN death)) (PP (IN in) (NP (NN tumor) (NN cell) (NNS lines))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD investigated) (ADVP (RB here)) (SBAR (IN whether) (S (NP (CD 6) (JJ popular) (NN antitumor) (NNS compounds)) (VP (VB modify) (NP (NP (DT the) (JJ cytotoxic) (NN activity)) (PP (IN of) (NP (NN NaF))) (PP (IN against) (NP (NP (NP (JJ human) (JJ squamous) (NN cell) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HSC-2)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ human) (JJ promyelocytic) (NN leukemia) (-LRB- -LRB-) (NN HL-60) (-RRB- -RRB-)) (NN cell) (NNS lines)))))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Cytotoxic) (NNS concentrations)) (PP (IN of) (NP (NP (NN cisplatin)) (, ,) (NP (NN etoposide)) (, ,) (NP (NN doxorubicin)) (CC or) (NP (NP (NN peplomycin)) (PRN (-LRB- -LRB-) (ADVP (RB tentatively)) (VP (VBN termed) (PP (IN as) (NP (NN Group) (CD I) (NNS compounds)))) (-RRB- -RRB-)))))) (, ,) (CONJP (CC but) (RB not)) (NP (NP (NP (NN methotrexate)) (CC and) (NP (NN 5-FU))) (PRN (-LRB- -LRB-) (ADVP (RB tentatively)) (VP (VBN termed) (PP (IN as) (NP (NN Group) (CD II) (NNS compounds)))) (-RRB- -RRB-))) (, ,)) (VP (VBD enhanced) (NP (NP (DT the) (JJ cytotoxic) (NN activity)) (PP (IN of) (NP (NN NaF)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN NaF)) (CC and) (NP (NN Group) (NN I))) (NNS compounds)) (VP (VBD induced) (NP (JJ internucleosomal) (NN DNA) (NN fragmentation)) (PP (IN in) (NP (NN HL-60) (NNS cells))) (, ,) (SBAR (IN whereas) (S (NP (NN Group) (CD II) (NNS compounds)) (VP (VBD were) (ADJP (JJ inactive)) (PP (ADVP (RB even)) (IN in) (DT the) (NN presence) (IN of) (NP (NN NaF)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Most) (NN Group) (NN I) (NNS compounds)) (PP (IN except) (NP (NP (NN doxorubicin)) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBD induced) (NP (NN DNA) (NN fragmentation)) (ADVP (ADVP (RBR less) (RB effectively)) (PP (IN than) (NP (NNS others))))))) (-RRB- -RRB-)))) (VP (VBD activated) (NP (NN caspase) (CD 3)) (ADVP (ADVP (RBR more) (RB efficiently)) (PP (IN than) (NP (NN Group) (NN II) (NNS compounds)))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Caspase) (CD 8)) (-LRB- -LRB-) (VP (VBN involved) (PP (IN in) (NP (JJ non-mitochondrial) (JJ extrinsic) (NN pathway)))) (-RRB- -RRB-)) (CC and) (NP (NP (NN caspase) (CD 9)) (-LRB- -LRB-) (VP (VBN involved) (PP (IN in) (NP (JJ mitochondrial) (JJ intrinsic) (NN pathway)))) (-RRB- -RRB-))) (VP (VBD were) (ADVP (RB also)) (VP (VBN activated) (, ,) (CC but) (PP (TO to) (NP (DT a) (ADJP (RB much) (JJR lesser)) (NN extent)))))) (. .)))
(S1 (S (S (NP (NN NaF)) (VP (VBD reduced) (NP (DT the) (NN glucose) (NN consumption)) (PP (IN at) (NP (JJ early) (NN stage))) (, ,) (ADVP (RB possibly)) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN glycolysis))))))) (, ,) (IN whereas) (S (NP (NP (NN cisplatin)) (CC and) (NP (NN etoposide))) (VP (VBD reduced) (NP (DT the) (NN glucose) (NN consumption)) (PP (IN at) (NP (JJ later) (NN stage))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (JJ early) (NN decline)) (PP (IN of) (NP (NN glucose) (NN consumption)))) (VP (VBZ is) (ADVP (RB rather)) (ADJP (JJ specific) (PP (TO to) (NP (NN NaF))))))))))) (. .)))
